Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wenping Gong

Showing results (1-10 of 116) with videos related to

Pageof 12
Sort By:
The Lancet. Infectious Diseases|March 8, 2025
Evaluating H56:IC31 vaccine in tuberculosis recurrence preventionWenping Gong, Jingli Du
Journal of Korean Medical Science|October 31, 2023
Excluding Participants With Mycobacteria Infections From Clinical Trials: A Critical Consideration in Evaluating the Efficacy of BCG Against COVID-19Wenping Gong, Jingli Du
The Lancet. Global Health|April 18, 2025
Diagnostic dilemmas and strain diversity in the MTBVAC phase 1b-2a trial in adultsYanhua Liu, Wenping Gong
Vaccines|December 24, 2025
Tuberculosis Vaccines: Multidimensional Exploration and Breakthroughs from Innovative Design to Evaluation SystemsWenping Gong, Ashok Aspatwar
Journal of Korean Medical Science|May 11, 2021
Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines?Zaixing Jia, Wenping Gong
The Indian Journal of Tuberculosis|June 8, 2021
Is the tuberculosis vaccine BCG an alternative weapon for developing countries to defeat COVID-19?Wenping Gong, Xueqiong Wu
Hepatology Communications|June 6, 2022
Child hepatitis of unknown origin may be due to insufficient understanding of adenovirus pathogenicityYong Qi, Wenping Gong
Frontiers in Microbiology|November 8, 2021
Differential Diagnosis of Latent Tuberculosis Infection and Active Tuberculosis: A Key to a Successful Tuberculosis Control StrategyWenping Gong, Xueqiong Wu
The Lancet. Infectious Diseases|November 28, 2023
Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis controlWenping Gong, Jingli Du
Journal of Immunology Research|June 13, 2022
Cellular Immunity of Patients with Tuberculosis Combined with DiabetesPeng Cheng, Liang Wang, Wenping Gong
Pageof 12

Showing results (1-10 of 116) with videos related to

Sort By:
Pageof 12
The Lancet. Infectious Diseases|March 8, 2025
Evaluating H56:IC31 vaccine in tuberculosis recurrence preventionWenping Gong, Jingli Du
Journal of Korean Medical Science|October 31, 2023
Excluding Participants With Mycobacteria Infections From Clinical Trials: A Critical Consideration in Evaluating the Efficacy of BCG Against COVID-19Wenping Gong, Jingli Du
The Lancet. Global Health|April 18, 2025
Diagnostic dilemmas and strain diversity in the MTBVAC phase 1b-2a trial in adultsYanhua Liu, Wenping Gong
Vaccines|December 24, 2025
Tuberculosis Vaccines: Multidimensional Exploration and Breakthroughs from Innovative Design to Evaluation SystemsWenping Gong, Ashok Aspatwar
Journal of Korean Medical Science|May 11, 2021
Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines?Zaixing Jia, Wenping Gong
The Indian Journal of Tuberculosis|June 8, 2021
Is the tuberculosis vaccine BCG an alternative weapon for developing countries to defeat COVID-19?Wenping Gong, Xueqiong Wu
Hepatology Communications|June 6, 2022
Child hepatitis of unknown origin may be due to insufficient understanding of adenovirus pathogenicityYong Qi, Wenping Gong
Frontiers in Microbiology|November 8, 2021
Differential Diagnosis of Latent Tuberculosis Infection and Active Tuberculosis: A Key to a Successful Tuberculosis Control StrategyWenping Gong, Xueqiong Wu
The Lancet. Infectious Diseases|November 28, 2023
Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis controlWenping Gong, Jingli Du
Journal of Immunology Research|June 13, 2022
Cellular Immunity of Patients with Tuberculosis Combined with DiabetesPeng Cheng, Liang Wang, Wenping Gong
Pageof 12